AKT1 and breast carcinoma: Based on the need of precise isoform-specific inhibitors, especially in the treatment of the most aggressive breast cancers, the role of Vav1 as a potential down-regulator of individual Akt isozymes was investigated in the MDA-MB-231 cell line, highly invasive and with a triple negative phenotype.